Pieter Jaap Gaillard
Fondateur chez Mireca Medicines GmbH
Profil
Pieter Jaap Gaillard was the founder of to-BBB technologies BV, founded in 2003, where he held the title of Chief Scientific Officer.
He is also the founder of Mireca Medicines GmbH, founded in 2017, where he currently holds the title of Chairman-Supervisory Board.
Dr. Gaillard has a doctorate degree from the University of Leiden and a graduate degree from the University of Utrecht.
Postes actifs de Pieter Jaap Gaillard
| Sociétés | Poste | Début |
|---|---|---|
Mireca Medicines GmbH
 Mireca Medicines GmbH Pharmaceuticals: MajorHealth Technology Mireca Medicines GmbH develops treatment for hereditary eye disease. The company was founded by François Paquet-Durand, Pieter Jaap Gaillard and Barbara Brunnhuber in 2017 and is headquartered in Tubingen, | Fondateur | 01/01/2017 |
Anciens postes connus de Pieter Jaap Gaillard
| Sociétés | Poste | Fin |
|---|---|---|
to-BBB technologies BV
 to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Fondateur | - |
Formation de Pieter Jaap Gaillard
| University of Utrecht | Graduate Degree |
| University of Leiden | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
to-BBB technologies BV
to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
Mireca Medicines GmbH
Mireca Medicines GmbH Pharmaceuticals: MajorHealth Technology Mireca Medicines GmbH develops treatment for hereditary eye disease. The company was founded by François Paquet-Durand, Pieter Jaap Gaillard and Barbara Brunnhuber in 2017 and is headquartered in Tubingen, | Health Technology |
